These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17266388)

  • 1. Preferred drug lists and Medicaid prescriptions.
    Abdelgawad T; Egbuonu-Davis L
    Pharmacoeconomics; 2006; 24 Suppl 3():55-63. PubMed ID: 17266388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?
    Ketcham JD; Epstein AJ
    Pharmacoeconomics; 2006; 24 Suppl 3():27-40. PubMed ID: 17266386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicaid preferred drug lists: cost containment and side effects.
    Headen AE
    Pharmacoeconomics; 2006; 24 Suppl 3():1-3. PubMed ID: 17266384
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicaid preferred drug lists' costs to physicians.
    Ketcham JD; Epstein AJ
    Med Care; 2008 Jan; 46(1):9-16. PubMed ID: 18162850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods.
    Headen AE; Masia NA; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():41-53. PubMed ID: 17266387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferred drug lists: potential impact on healthcare economics.
    Ovsag K; Hydery S; Mousa SA
    Vasc Health Risk Manag; 2008; 4(2):403-13. PubMed ID: 18561515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Medicaid preferred drug lists on therapeutic adherence.
    Ridley DB; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():65-78. PubMed ID: 17266389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.
    Lichtenberg FR
    Am J Manag Care; 2005 Jan; 11 Spec No():SP7-13. PubMed ID: 15700904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical Research and Manufacturers of America v. Walsh: the Supreme Court allows the states to proceed with expanding access to drugs.
    Jost TS
    Yale J Health Policy Law Ethics; 2004; 4(1):69-84. PubMed ID: 15052860
    [No Abstract]   [Full Text] [Related]  

  • 12. Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.
    Roy S; Madhavan SS
    Pharmacoeconomics; 2008; 26(4):281-96. PubMed ID: 18370564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Providing pharmaceutical care for indigent patients: a roundtable discussion.
    Hatwig CA; McAllister JC; Miller DE; Wilson AL
    Am J Health Syst Pharm; 2001 May; 58(10):867-78. PubMed ID: 11381491
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.
    Soumerai SB
    Health Aff (Millwood); 2004; 23(1):135-46. PubMed ID: 15002636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. States' control of prescription drug spending: a heterogeneous approach.
    Morden NE; Sullivan SD
    Health Aff (Millwood); 2005; 24(4):1032-8. PubMed ID: 16012143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana.
    Virabhak S; Shinogle JA
    Am J Manag Care; 2005 Jan; 11 Spec No():SP14-20. PubMed ID: 15700905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB; Avorn J; Ross-Degnan D; Gortmaker S
    N Engl J Med; 1987 Aug; 317(9):550-6. PubMed ID: 3302713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number Of Medicaid Prescriptions Grew, Drug Spending Was Steady In Medicaid Expansion States.
    Wen H; Borders TF; Druss BG
    Health Aff (Millwood); 2016 Sep; 35(9):1604-7. PubMed ID: 27605639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.